title: [Consumption of a DHA-enriched milk drink by pregnant and lactating women, on the fatty acid composition of red blood cells, breast milk, and in the newborn].
abstract: EPA and DHA consumption in Chile is markedly below international daily intake recommendations. For improvement of such low intake level, we developed a fortified powdered dairy drink, containing 60 mg/serving of DHA and 14 mg/serving of EPA.
  
  
  OBJECTIVE
  to evaluate the effects of DHA consumption during pregnancy, parturition, and in the newborn, on lipid composition of red blood cell membranes and levels of DHA and EPA on human milk during lactation. One hundred and seventy five (175) pregnant women received 2 kg/month of the fortified powdered dairy drink (GE), and 177 received the regular milk provided by the Ministry of Health (GC). We monitored daily intake of the dairy drink and all other sources of DHA and EPA in the diet, and measured general biological indicators during pregnancy, parturition, and in the new born. On a subsample of 14 women on each group (GE and GC), we measured fatty acid composition of red blood cell membranes after 0 and 60 days of consumption with the fortified dairy drink, and levels of DHA and EPA on human milk after 2 months of lactation. Of all women in the study, 16% had no consumption of fish, and 53% had no consumption of sea food. Less than 25% of all women had fish on a weekly basis. Consumption of the fortified dairy drink tripled intake of DHA, from 48.8 mg/day (CI 38.7-57.5) to 147.8 mg/day (CI 128.4-167.9) (p<0.001). The GE group had a higher content of DHA on the phospholipids of red blood cell membranes: 11.1% (CI 10.2-13.0) versus 17.9% (CI 12.9-23.0) (p<0.002). Concentration of DHA and omega-3 fatty acids increased 50% in milk of women consuming the fortified dairy drink (p<0.06). There was alower incidence of preterm parturitions on the GE group (2.8 vs 10.6%), but without statistical significance. The consumption of the fortified dairy drink produced a significant increase of DHA consumption during pregnancy and lactation, and an improved composition of red blood cell membranes, as well as in human milk, proving to be an appropriate intervention strategy for the target population.
authors.affiliation: Facultad Medicina, Universidad Chile, Gerencia Desarrollo & Calidad, Watt's SA, Departamento de Alimentos y Nutrición, Ministerio de Salud, Santiago, Chile.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Atalah S
authors.forename: Marcela
authors.initials: M
authors.lastname: Araya B
authors.forename: Gastón
authors.initials: G
authors.lastname: Rosselot P
authors.forename: Héctor
authors.initials: H
authors.lastname: Araya L
authors.forename: Gloria
authors.initials: G
authors.lastname: Vera A
authors.forename: Ramón
authors.initials: R
authors.lastname: Andreu R
authors.forename: Catalina
authors.initials: C
authors.lastname: Barba G
authors.forename: Lorena
authors.initials: L
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002677:Chile; D015331:Cohort Studies; D004032:Diet; D004042:Dietary Fats, Unsaturated / Q000032:analysis; D004281:Docosahexaenoic Acids / Q000008:administration & dosage* / Q000378:metabolism; D015118:Eicosapentaenoic Acid / Q000008:administration & dosage* / Q000378:metabolism; D004910:Erythrocyte Membrane / Q000737:chemistry*; D005260:Female; D005527:Food, Fortified; D006801:Humans; D007231:Infant, Newborn; D008895:Milk, Human / Q000737:chemistry*; D011247:Pregnancy; D011256:Pregnancy Outcome
chemical_list: D004042:Dietary Fats, Unsaturated; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid